Immunosuppressants to Postoperative Infection & Death

Status Recruiting

Clinical Trial Summary

The goal of this observational study is to explore the different immunosuppressive agents and related outcomes in organ transplantation patients in Taiwan. The main question it aims to answer is the risk of different immunosuppressive agents for infection and survival after transplant. The study enrolled patients who underwent solid organ transplant (SOT), kidney (ICD-9-CM code V42.0), liver (ICD-9-CM code V42.7), or lung (ICD-9-CM code V42.6) transplants. We employed propensity score matching (PSM) to establish a matched cohort. The study will compare SOT patients and general patients to explore the risk of different immunosuppressive agents for infection and survival.

Clinical Trial Description

This study used secondary data from the Longitudinal Health Insurance Database (LHID), a subset of the NHIRD provided by the Health and Welfare Data Science Center (HWDC) of the Ministry of Health and Welfare in Taiwan. The HWDC encrypts personally identifying data to protect the privacy of beneficiaries. The database includes detailed clinical records from both the inpatient and outpatient claims of the beneficiaries of Taiwan's National Health Insurance program. This program has provided coverage for up to 99% of the country's population since 1995. The NHIRD can serve as a foundation for the procurement of real-world evidence to support clinical decisions and health-care policy-making. Diagnostic data within the NHIRD from before 2016 and from 2016 or later are respectively coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. The database was provided by the HWDC under license and so cannot be made freely available. Requests for access to these data should be made to HWDC (https://dep.mohw.gov.tw/dos/cp-5119-59201-113.html). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06121804
Study type	Observational
Source	Chung Shan Medical University
Contact	Chien-Ying Lee, PhD
Phone	886-4-24730022
Email	cshd015@csmu.edu.tw
Status	Recruiting
Phase
Start date	December 20, 2021
Completion date	December 20, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00987103` - Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients	Phase 1
Completed	`NCT03699839` - Reducing the Burden of Influenza After Solid-Organ Transplantation	Phase 2/Phase 3
Completed	`NCT01633424` - The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT)
Completed	`NCT01254955` - Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients	N/A
Completed	`NCT00948883` - Study of Cancers After Solid Organs Transplants	N/A
Recruiting	`NCT02314949` - Leuven Tolerogenic Protocol for Intestinal Transplantation	N/A
Recruiting	`NCT01283295` - Immune Monitoring and Assay Development in Organ Transplant Recipients
Not yet recruiting	`NCT03861962` - Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
Completed	`NCT01123187` - Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation	N/A
Completed	`NCT00213304` - The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation	Phase 3
Completed	`NCT01515072` - Remote Ischemic Preconditioning in Neurological Death Organ Donors	N/A
Completed	`NCT00904579` - Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Recruiting	`NCT04687865` - Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)
Recruiting	`NCT00611494` - Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors	Phase 4
Completed	`NCT02852902` - Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.
Completed	`NCT05685888` - Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation
Recruiting	`NCT00792064` - Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation	N/A
Completed	`NCT00734396` - Mesenchymal Stem Cells and Subclinical Rejection	Phase 1/Phase 2
Completed	`NCT00286871` - Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen	Phase 1
Recruiting	`NCT03997253` - Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Immunosuppressants to Postoperative Infection and Death

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms